Gemcitabine pharmacogenomics

Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics

Judith A. Gilbert, Oreste E. Salavaggione, Yuan Ji, Linda L. Pelleymounter, Bruce W. Eckloff, Eric D Wieben, Matthew M. Ames, Richard M Weinshilboum

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Purpose: Gemcitabine is a nucleoside analogue with activity against solid tumors. Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD). We set out to study the pharmacogenomics of CDA and DCTD. Experimental Design: The genes encoding CDA and DCTD were resequenced using DNA from 60 African American and 60 Caucasian American subjects. Expression constructs were created for nonsynonymous coding single nucleotide polymorphisms (cSNP) and reporter gene constructs were created for 5′-flanking region polymorphisms. Functional genomic studies were then conducted after the transfection of mammalian cells. Results: CDA resequencing revealed 17 polymorphisms, including one common nonsynonymous cSNP, 79 A>C (Lys27Gln). Recombinant Gln27 CDA had 66 ± 5.1% (mean ± SE) of the wild-type (WT) activity for gemcitabine but without a significant decrease in level of immunoreactive protein. The apparent Km (397 ± 40 μmol/L) for the Gln27 allozyme was significantly higher than that for the WT (289 ± 20 μmol/L; P < 0.025). CDA 5′-flanking region reporter gene studies showed significant differences among 5′-flanking region haplotypes in their ability to drive transcription. There were 29 SNPs in DCTD, including one nonsynonymous cSNP, 172 A>G (Asn58Asp), in Caucasian American DNA. Recombinant Asp58 DCTD had 11 ± 1.4% of WT activity for gemcitabine monophosphate with a significantly elevated level of immunoreactive protein. No DCTD polymorphisms were observed in the initial 500 bp of the 5′-flanking region. Conclusions: These results suggest that pharmacogenomic variation in the deamination of gemcitabine and its monophosphate might contribute to variation in therapeutic response to this antineoplastic agent.

Original languageEnglish (US)
Pages (from-to)1794-1803
Number of pages10
JournalClinical Cancer Research
Volume12
Issue number6
DOIs
StatePublished - Mar 15 2006

Fingerprint

gemcitabine
DCMP Deaminase
Cytidine Deaminase
Pharmacogenetics
Genomics
Genes
5' Flanking Region
Single Nucleotide Polymorphism
Deamination
DNA
Reporter Genes
Nucleosides
African Americans
Antineoplastic Agents
Isoenzymes
Transfection
Proteins
Research Design
Phosphorylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gemcitabine pharmacogenomics : Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. / Gilbert, Judith A.; Salavaggione, Oreste E.; Ji, Yuan; Pelleymounter, Linda L.; Eckloff, Bruce W.; Wieben, Eric D; Ames, Matthew M.; Weinshilboum, Richard M.

In: Clinical Cancer Research, Vol. 12, No. 6, 15.03.2006, p. 1794-1803.

Research output: Contribution to journalArticle

Gilbert, Judith A. ; Salavaggione, Oreste E. ; Ji, Yuan ; Pelleymounter, Linda L. ; Eckloff, Bruce W. ; Wieben, Eric D ; Ames, Matthew M. ; Weinshilboum, Richard M. / Gemcitabine pharmacogenomics : Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 6. pp. 1794-1803.
@article{b122106d8b5c48088ce2fdfe3164a3db,
title = "Gemcitabine pharmacogenomics: Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics",
abstract = "Purpose: Gemcitabine is a nucleoside analogue with activity against solid tumors. Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD). We set out to study the pharmacogenomics of CDA and DCTD. Experimental Design: The genes encoding CDA and DCTD were resequenced using DNA from 60 African American and 60 Caucasian American subjects. Expression constructs were created for nonsynonymous coding single nucleotide polymorphisms (cSNP) and reporter gene constructs were created for 5′-flanking region polymorphisms. Functional genomic studies were then conducted after the transfection of mammalian cells. Results: CDA resequencing revealed 17 polymorphisms, including one common nonsynonymous cSNP, 79 A>C (Lys27Gln). Recombinant Gln27 CDA had 66 ± 5.1{\%} (mean ± SE) of the wild-type (WT) activity for gemcitabine but without a significant decrease in level of immunoreactive protein. The apparent Km (397 ± 40 μmol/L) for the Gln27 allozyme was significantly higher than that for the WT (289 ± 20 μmol/L; P < 0.025). CDA 5′-flanking region reporter gene studies showed significant differences among 5′-flanking region haplotypes in their ability to drive transcription. There were 29 SNPs in DCTD, including one nonsynonymous cSNP, 172 A>G (Asn58Asp), in Caucasian American DNA. Recombinant Asp58 DCTD had 11 ± 1.4{\%} of WT activity for gemcitabine monophosphate with a significantly elevated level of immunoreactive protein. No DCTD polymorphisms were observed in the initial 500 bp of the 5′-flanking region. Conclusions: These results suggest that pharmacogenomic variation in the deamination of gemcitabine and its monophosphate might contribute to variation in therapeutic response to this antineoplastic agent.",
author = "Gilbert, {Judith A.} and Salavaggione, {Oreste E.} and Yuan Ji and Pelleymounter, {Linda L.} and Eckloff, {Bruce W.} and Wieben, {Eric D} and Ames, {Matthew M.} and Weinshilboum, {Richard M}",
year = "2006",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1969",
language = "English (US)",
volume = "12",
pages = "1794--1803",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Gemcitabine pharmacogenomics

T2 - Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics

AU - Gilbert, Judith A.

AU - Salavaggione, Oreste E.

AU - Ji, Yuan

AU - Pelleymounter, Linda L.

AU - Eckloff, Bruce W.

AU - Wieben, Eric D

AU - Ames, Matthew M.

AU - Weinshilboum, Richard M

PY - 2006/3/15

Y1 - 2006/3/15

N2 - Purpose: Gemcitabine is a nucleoside analogue with activity against solid tumors. Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD). We set out to study the pharmacogenomics of CDA and DCTD. Experimental Design: The genes encoding CDA and DCTD were resequenced using DNA from 60 African American and 60 Caucasian American subjects. Expression constructs were created for nonsynonymous coding single nucleotide polymorphisms (cSNP) and reporter gene constructs were created for 5′-flanking region polymorphisms. Functional genomic studies were then conducted after the transfection of mammalian cells. Results: CDA resequencing revealed 17 polymorphisms, including one common nonsynonymous cSNP, 79 A>C (Lys27Gln). Recombinant Gln27 CDA had 66 ± 5.1% (mean ± SE) of the wild-type (WT) activity for gemcitabine but without a significant decrease in level of immunoreactive protein. The apparent Km (397 ± 40 μmol/L) for the Gln27 allozyme was significantly higher than that for the WT (289 ± 20 μmol/L; P < 0.025). CDA 5′-flanking region reporter gene studies showed significant differences among 5′-flanking region haplotypes in their ability to drive transcription. There were 29 SNPs in DCTD, including one nonsynonymous cSNP, 172 A>G (Asn58Asp), in Caucasian American DNA. Recombinant Asp58 DCTD had 11 ± 1.4% of WT activity for gemcitabine monophosphate with a significantly elevated level of immunoreactive protein. No DCTD polymorphisms were observed in the initial 500 bp of the 5′-flanking region. Conclusions: These results suggest that pharmacogenomic variation in the deamination of gemcitabine and its monophosphate might contribute to variation in therapeutic response to this antineoplastic agent.

AB - Purpose: Gemcitabine is a nucleoside analogue with activity against solid tumors. Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD). We set out to study the pharmacogenomics of CDA and DCTD. Experimental Design: The genes encoding CDA and DCTD were resequenced using DNA from 60 African American and 60 Caucasian American subjects. Expression constructs were created for nonsynonymous coding single nucleotide polymorphisms (cSNP) and reporter gene constructs were created for 5′-flanking region polymorphisms. Functional genomic studies were then conducted after the transfection of mammalian cells. Results: CDA resequencing revealed 17 polymorphisms, including one common nonsynonymous cSNP, 79 A>C (Lys27Gln). Recombinant Gln27 CDA had 66 ± 5.1% (mean ± SE) of the wild-type (WT) activity for gemcitabine but without a significant decrease in level of immunoreactive protein. The apparent Km (397 ± 40 μmol/L) for the Gln27 allozyme was significantly higher than that for the WT (289 ± 20 μmol/L; P < 0.025). CDA 5′-flanking region reporter gene studies showed significant differences among 5′-flanking region haplotypes in their ability to drive transcription. There were 29 SNPs in DCTD, including one nonsynonymous cSNP, 172 A>G (Asn58Asp), in Caucasian American DNA. Recombinant Asp58 DCTD had 11 ± 1.4% of WT activity for gemcitabine monophosphate with a significantly elevated level of immunoreactive protein. No DCTD polymorphisms were observed in the initial 500 bp of the 5′-flanking region. Conclusions: These results suggest that pharmacogenomic variation in the deamination of gemcitabine and its monophosphate might contribute to variation in therapeutic response to this antineoplastic agent.

UR - http://www.scopus.com/inward/record.url?scp=33645692656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645692656&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1969

DO - 10.1158/1078-0432.CCR-05-1969

M3 - Article

VL - 12

SP - 1794

EP - 1803

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -